Kinder Morgan Energy Partners, L.P. Message Board

this will be growth from .5 bcf/d in 2004, to 3 bcf/d in 2013, to 7 bcf/d by 2015/2016. this is with no other new/additional projects than what is currently contracted. this was from investors day

".....New Research Proves Clinical Pathways Can Reduce Cancer Care Costs and Improve Quality While Increasing Physician Reimbursement
Cardinal Health Specialty Solutions Shares Powerful New Cancer-Care Research at 2013 American Society of Clinical Oncology (ASCO) Annual Meeting

DUBLIN, Ohio, May 21, 2013 /PRNewswire/ -- With the cost of cancer care projected to increase to $170 billion by 20201, many in the healthcare industry are looking for ways to curb that cost curve — while maintaining quality of care for cancer patients and preserving fair compensation for physicians. New research being featured later this month in poster presentations and abstracts at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) proves that it is possible to meet all three of these seemingly contrary goals.

Cardinal Health Specialty Solutions and CareFirst BlueCross BlueShield (CareFirst), one of the largest health insurers in the Mid-Atlantic, recently completed a series of studies on the effectiveness of the nation's first clinical pathways program for oncology, which they jointly launched in 2008. Physicians within the CareFirst network worked together to develop clinical pathways — or evidence-based treatment regimens — for the treatment of breast, lung and colon cancers.

The new research shows that through the use of the Clinical Pathways program, CareFirst reduced its overall costs for treating breast, lung and colon cancers by 15 percent. These savings were primarily achieved through a 7 percent decline in emergency room visits, shorter lengths of stay in the hospital, increased use of generic medications and more appropriate use of chemotherapy. Although the overall drug spend was reduced, the reimbursement to physicians increased for both branded and generic drugs, and physicians received higher reimbursement overall.

The authors of the research contend that payor-physician collaboration was a significant factor behind the success..."

msg 30692 of 30692 at 6/13/2013 5:05:53 PM by

MattZN from mlp investorvillage board



In response to msg 30691 by clambo view thread
Re: LINE just got ugly with volume
I do think that the volatility is masking longer-term trends towards normalization. EVEP's yield is moving similarly. But, for example, over the last month OKE has actually dropped more than LINE has (though not as much as EVEP). OKE is a large-cap GP that isn't even remotely near the E&P space. The similarity is that OKE had run up a huge amount, to the point where its yield was scraping the bottom of the barrel.

Because of that I believe that what we are seeing in the medium and longer-term is as much a normalization effect as it is an interest rate effect.

As to WHY many names in the E&P space is sitting in the 10%+ yield range, the answer to that is obvious: Because due to debt/leverage levels and a lack of cash-flow, that space has become the most sensitive to interest rate changes. And I'm not talking long-term debt here (though that definitely matters). I'm talking their revolver plus any floating debt they might have. Bluntly speaking, investors are pricing these issues with the expectation that they will have to reduce their distribution.

-Matt

rlp2451 • 3 hours ago on evep yahoo board

OT: Antero Resources Files $1B IPO

We are an independent natural gas and oil company engaged in the exploitation, development and acquisition of natural gas, NGLs and oil properties located in the Appalachian Basin in West Virginia, Ohio and Pennsylvania. We are focused on creating shareholder value through the development of our large portfolio of repeatable, low cost, liquids-rich drilling opportunities in two of the premier North American shale plays. We currently hold approximately 317,000 net acres in the southwestern core of the Marcellus Shale and approximately 94,000 net acres in the core of the Utica Shale. In addition, we estimate that approximately 194,000 net acres of our Marcellus Shale leasehold are prospective for the slightly shallower Upper Devonian Shale. As of December 31, 2012, our estimated aggregate proved, probable and possible reserves were 26.1 Tcfe, and our 4.9 Tcfe of proved reserves were 21% proved developed and 75% natural gas. As of December 31, 2012, our drilling inventory consisted of 4,923 identified potential horizontal well locations, approximately 79% of which are liquids-rich drilling opportunities

need to go to investorvillage navb regular board to read/access references

"....clinical trials testing the benefits of clearing out a protein that accumulates in the brains of patients with Alzheimer’s disease shared similar outcomes: failure “If we are right that a buildup of amyloid causes Alzheimer’s disease, then why were all these trials failing?” he asked rhetorically, answering: “Because by the time people qualified for treatment, by the time they already had the clinical diagnosis of Alzheimer’s disease, it was too late. The damage had been done.

That insight, combined with imaging advances that allow experts to measure levels of amyloid in the brain, has changed how researchers conduct clinical trials for Alzheimer’s, with their research focus has shifted from testing on those with dementia, now recognized as a late stage of the disease, to people who have detectable amyloid but no apparent symptoms of Alzheimer’s.

Since the presence of amyloid in the brain can precede any symptoms of Alzheimer’s disease or dementia by up to 15 years, researchers hope that early intervention can halt or slow its buildup. “It’s a huge change in the design of treatment trials,” Dr. Devous said, noting that one of the biggest advances came a year ago when the Food and Drug Administration approved the first amyloid imaging agent, called Amyvid, for use in positron emission tomography (PET) scans. Amyvid is a radiopharmaceutical that binds to amyloid plaque and “lights up” on a PET scan, allowing radiologists to identify the presence of the harmful protein. It’s being used both clinically and in research projects..."

A combination of the two so they can make a deal in the near term and one in the long term? or just to pay off/down debt?